Should I go on Wegovy? A clear guide to making the decision

What does Wegovy actually do, and is that what you need?

Wegovy contains semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. GLP-1 is a hormone your gut releases after eating; semaglutide mimics it, signalling to your brain that you're full sooner and slowing gastric emptying. The result, for most people, is a measurable and sustained fall in appetite. It is not a stimulant, not a fat-blocker, and not a metabolism booster in the traditional sense. It works best when combined with genuine changes to diet and activity — that combination is baked into the clinical trials on which the UK licence is based.

Whether that mechanism is what your body needs is a clinical question. Some people have a very strong physiological response; others find the appetite effect milder. A prescriber looking at your full health picture (your weight history, any existing conditions, current medications) is far better placed than a webpage to answer that. What a webpage can do is tell you what to expect, so you walk into that assessment informed. If you are weighing up whether you should use Wegovy given your circumstances, that page takes you through the key considerations in more depth. You can also read more about how semaglutide works if you want the mechanism in more depth.

One thing worth knowing: the medicine starts at a low dose (0.25mg) and is titrated upward over several months by your prescriber. The early weeks are not representative of the full effect. Many people find the side-effect profile most noticeable at the beginning and settles considerably from there.

Does your situation actually meet the licensed criteria?

The UK licence for Wegovy covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 with at least one weight-related condition, things like high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance, which your prescriber will factor in.

Those are the licence boundaries. Within them, a prescriber still needs to be satisfied that Wegovy is appropriate for you specifically. Certain conditions (a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or a history of pancreatitis) require careful discussion, and in some cases mean Wegovy isn't the right choice. The NHS medicines page on semaglutide sets out the full contraindication list in patient-friendly language.

If you're unsure which treatment might suit your BMI and medical background, it's worth exploring the treatment options side by side before committing to a specific medicine.

A word on NHS access: NICE recommends semaglutide (TA875) within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above and at least one weight-related comorbidity. NHS waiting lists for this pathway are typically long. Many people who meet the private licence criteria but not the NHS-specific thresholds, or who simply don't want to wait, access it privately through a regulated online pharmacy instead.

What are the side effects worth weighing before you decide?

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping. Most people notice them most after starting or after a dose increase, and they often settle within a couple of weeks. If you are still working out whether you should take Wegovy once you have read about the side effects, that page helps you think through the personal trade-offs. They rarely disappear immediately, though, so it's worth going in with realistic expectations rather than hoping for a symptom-free start.

A smaller number of people experience fatigue, headaches or dizziness, particularly early on. Serious side effects are uncommon but worth knowing: the MHRA and NHS flag gallbladder problems and, in rare cases, acute pancreatitis, if you develop severe stomach pain that spreads to your back, get medical help promptly rather than waiting. You can report any suspected side effect via the MHRA Yellow Card scheme, which is open to patients directly.

For women who take an oral contraceptive pill: because GLP-1 medicines affect gastric emptying and can therefore affect how oral medications are absorbed, it is worth discussing your contraception with your prescriber before or at the point of starting treatment. This is not a reason to avoid Wegovy, but it is a practical detail that sometimes catches people by surprise.

If you find that progress stalls once you're established on treatment, our page on what happens if Wegovy isn't working covers the practical steps and the clinical thresholds that matter.

How do you actually think about cost in this decision?

Cost is a fair part of the decision, not a superficial one. Wegovy is a private prescription medicine for most people in the UK, and it's taken over months, not weeks. Eli Lilly's September 2025 list price increase shifted the market considerably, typical private prices across the sector now range roughly £149–£375 per month depending on the dose and provider, according to widely reported figures. That's a meaningful outlay to plan for, especially if you are still deciding whether getting Wegovy is the right call for your situation right now, including how the cost fits into your budget (some people time their first order around payday, which is completely sensible).

What matters alongside the headline figure is what's included. Some quoted prices exclude the consultation fee, the prescription, or ongoing clinical support. Our guide to what Wegovy actually costs in the UK breaks down what different price structures typically include and what questions are worth asking any provider before you start. The aim is to help you compare like with like, rather than be surprised by the total.

Once you feel ready to talk through your specific situation with a clinician, you can check your eligibility through a free consultation with our prescribers.